New mRNA flu vaccine shows promise in early human trial
NCT ID NCT06602531
First seen Oct 31, 2025 · Last updated May 18, 2026 · Updated 26 times
Summary
This study tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against a future pandemic flu. 212 healthy adults aged 18-80 received either the experimental vaccine or a licensed flu shot. Researchers monitored side effects and measured immune responses to find the best dose and schedule for further development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CTI Clinical Research Center
Cincinnati, Ohio, 45212, United States
-
Tekton Research
Longmont, Colorado, 80501, United States
-
Velocity Clinical Research
La Mesa, California, 91942, United States
-
Velocity Clinical Research
San Bernardino, California, 92408, United States
Conditions
Explore the condition pages connected to this study.